In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Hybrid left ventricular reconstruction for the treatment of ischemic cardiomyopathy: long-term results from one center

Session HFA Discoveries - ePosters

Speaker Jan Naar

Event : HFA Discoveries 2020

  • Topic : heart failure
  • Sub-topic : Ventricular Remodeling
  • Session type : ePosters

Authors : J Naar (Prague,CZ), I Skalsky (Prague,CZ), F Malek (Prague,CZ), K Van Bladel (San Ramon,US), L Annest (San Ramon,US), P Moucka (Prague,CZ), A Kruger (Prague,CZ), T Mraz (Prague,CZ), P Neuzil (Prague,CZ)

Authors:
J Naar1 , I Skalsky2 , F Malek1 , K Van Bladel3 , L Annest3 , P Moucka1 , A Kruger1 , T Mraz1 , P Neuzil1 , 1Na Homolce Hospital, Department of Cardiology - Prague - Czechia , 2Na Homolce Hospital, Cardiosurgery - Prague - Czechia , 3BioVentrix, Inc. - San Ramon - United States of America ,

Citation:

Background

The evidence for surgical aneurysmectomy added to coronary artery bypass grafting procedure in patients with ischemic cardiomyopathy due to anterior myocardial infarction is ambiguous.

Purpose

The authors present 5-year results of hybrid minimally invasive left ventricular (LV) reconstruction performed as isolated procedure.

Methods

Heart failure patients with transmural post-infarction scar in left anterior descending (LAD) artery region were enrolled into the study. Main inclusion criteria were LV ejection fraction (EF) 15-45%, New York Heart Association (NYHA) class II-IV. Main exclusion criteria were LV trombus and myocardial infarction within 90 days prior enrollment. Scar tissue was excluded by Revivent TC system consisted of pairs of anchors implanted by internal jugular vein access from right side of interventricular septum (internal anchors) and left mini-thoracotomy (external anchors). Procedure was performed on beating heart. Transthoracic echocardiography, 6-minute walk test (6-MWT), Minnesota Living with Heart Failure Questionnaire (MLHFQ) and NT-proBNP level were evaluated pre-operatively and during subsequent follow-up visits.

Results

23 patients (15 males, mean age 59±11 years) were intervened between March 2014 and March 2019 in one heart center. System was successfully implanted in 22 subjects. On average, 2.8 anchor pairs were used for LV reconstruction. Mean operating time was 204±50 min. LV end-systolic volume index (LVESVI) was significantly reduced after 6 months (74.3±28 vs. 53.5±22 ml, p=0.02, n=18), 2 years (77.3±30 vs. 53.1±18 ml, p=0.02, n=14) as well as 5 years (72.4±11 vs. 54.5±11 ml, p=0.02, n=6). There was a trend towards LV EF increase. NYHA class ameliorated significantly throughout the follow-up (after 6 months 2.2±0.6 vs. 2.0±0.6, p=0.048, n=19; after 2 years 2.3±0.5 vs. 2.0±0.8, p=0.02, n=14; after 5 years 2.3±0.5 vs. 1.3±0.5, p=0.01, n=6), whereas 6-MWT, MLHFQ and NT-proBNP levels did not change.

Conclusion

Hybrid LV reconstruction with Revivent TC anchoring system is a feasible minimally invasive treatment method for selected patients with ischemic cardiomyopathy and transmural scar in LAD artery region, maintaining significant LVESVI reduction and NYHA class improvement during 5-year follow-up.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are